155058-02-9

Basic information

• Product Name: 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI)
• Synonyms: 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI);7,8-dihydro-1,6-naphthyridin-5(6H)-one;N-methyl-1-(1-methylpiperidin-4-yl)-2-(pyrrolidin-1-yl)ethanamine;1,6-Naphthyridin-5(6H)-one, 7,8-dihydro-;7,8-Dihydro-6H-[1,6]naphthyridin-5-one
• CAS NO: 155058-02-9
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.164
• Product Categories: PYRIDINE
• Mol File: 155058-02-9.mol

Chemical Properties

• Melting Point: 163-166 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 413.9±34.0 °C(Predicted)
• Appearance: /
• Density: 1.214±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.28±0.20(Predicted)
• CAS DataBase Reference: 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI)(155058-02-9)
• EPA Substance Registry System: 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI)(155058-02-9)

Safety Data

• Hazardous Substances Data: 155058-02-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI) is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure and reactivity make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI) is used as a starting material or intermediate in the development of new drugs. Its heterocyclic nature and potential for functionalization make it a promising candidate for the design of novel therapeutic agents with unique mechanisms of action.
Used in Chemical Research:
1,6-Naphthyridin-5(6H)-one,7,8-dihydro-(9CI) is also utilized in chemical research to study the properties and reactivity of naphthyridine-based compounds. This research can lead to a better understanding of the structure-activity relationships in this class of compounds and facilitate the discovery of new applications in various fields, including materials science and catalysis.

Upstream product

• 65719-09-7 methyl 2-methylnicotinate 
• 116986-08-4 methyl 2-(bromomethyl)pyridine-3-carboxylate 
• 38749-79-0 3-bromo-2-picoline 
• 103441-72-1 2-ethenyl-3-pyridinecarboxylic acid methyl ester 
• 379670-43-6 methyl 2-ethynylnicotinate 
• 379670-41-4 methyl 2-((trimethylsilyl)ethynyl)nicotinate 
• 1452-94-4 ethyl 2-chloronicotinate 
• 2942-59-8 2-chloronicotinic acid 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 

Downstream Products

• 1312751-81-7 C₁₈H₁₆N₂O 
• 1312751-82-8 C₁₇H₁₃ClN₂O 
• 1312751-83-9 C₁₇H₁₃ClN₂O 
• 1312751-84-0 C₁₇H₁₃ClN₂O 
• 1312751-85-1 C₁₈H₁₆N₂O₂ 
• 1312751-78-2 6-methyl-2-phenylethynyl-7,8-dihydro-6H-1,6-naphthyridin-5-one 
• 1312751-79-3 C₁₈H₁₆N₂O 
• 1312751-80-6 C₁₈H₁₆N₂O 
• 80957-68-2 5,6,7,8-tetrahydro-1,6-naphthyridine 
• 259809-44-4 7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 1036381-91-5 tert‐butyl 2‐oxo‐1,5,7,8‐tetrahydro‐1,6‐naphthyridine‐6(2H)‐carboxylate 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

INHIBITOR OF BTK AND MUTANTS THEREOF

The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2

As part of an effort to identify novel selective modulators of sirtuins, we synthesized and tested several isosteres and constrained analogues of nicotinamide. Biological data suggest that compound 2 is selective for Sirt3 over Sirt1 and Sirt2.

Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype

A series of metabotropic glutamate 5 receptor (mGluR5) allosteric ligands with positive, negative or no modulatory efficacy is described. The ability of this series to yield both mGluR5 PAMs and NAMs with single-digit nanomolar potency is unusual, and the

Ready access to 7,8-dihydro- and 1,2,3,4-tetrahydro-1,6-naphthyridine-5(6H) -ones from simple pyridine precursors

Short pathways are described for the synthesis of a representative example of each of the 7,8-dihydro- and 1,2,3,4-tetrahydro-1,6-naphthyridine-5(6H)-one ring systems from simple pyridine precursors. An attempted synthesis of the related 4,6-dihydro-1,6-naphthyridin-5(1H)-one ring system from a common intermediate was unsuccessful.

Dihydro- and tetrahydronaphthyridines

This invention concerns novel dihydro- and tetrahydronaphthyridines useful for enhancing the lethal effects on tumor cells to treatment causing DNA-damaging activity as with ionizing radiation or with a chemotherapeutic agent.